Rite Aid Corporation stock price

Rite Aid Corporation latest news:


  • 01/14/2018 12:09:21

    UPDATE 1-U.S. transport chief to unveil revised self-driving car guidelines

    DETROIT, Jan 14 (Reuters) - The Trump administration plans to unveil revised self-driving car guidelines this summer as the government works to rewrite regulations that pose legal barriers to robot vehicles, U.S. Transportation Secretary Elaine Chao said on Sunday.

  • 01/14/2018 11:30:15

    U.S. transit chief to unveil revised self-driving car guidelines

    The Trump administration plans to unveil revised self-driving car guidelines this summer as the government works to rewrite regulations that pose legal barriers to robot vehicles, U.S. Transportation Secretary Elaine Chao said on Sunday.

  • 01/04/2018 10:11:14

    Walgreens close to completing purchase of 1,900+ Rite Aid stores

    Walgreens is edging closer to completing its long-suffering deal to acquire a large chunk of rival Rite Aid's stores.        

  • 01/04/2018 09:30:20

    Rite Aid Whiffs Big on Q3 Revenues


  • 01/03/2018 16:19:32

    BRIEF-Rite Aid CFO- WE CONTINUE TO EXPECT REIMBURSEMENT RATE HEADWINDS

    Rite Aid(RAD): * COO- RAD WILL HAVE 2,569 STORES LOCATED PRIMARILY IN 8 KEY STATES, TO BE SERVED BY 6 DISTRIBUTION. * COO- WE HAVE BETTER PREDICTABILITY ON REIMBURSEMENT RATE AND ACCESS FOR THE COMING YEAR. * COO- OUR TOTAL MED D ENROLLMENT FOR THE 2018 PLAN YEAR HAS SURPASSED 500,000 LIVES.

  • 01/03/2018 08:40:57

    Netflix confirms sequel to blockbuster original film 'Bright'

    Netflix Inc. on Wednesday confirmed that it has ordered a sequel to it's Dec. 22 fantasy cop ride along original film "Bright." The sequel will again star Will Smith and Joel Edgerton, and David Ayer will write and direct it. Netflix said that "Bright," which was widely panned by critics and has a 28% Rotten Tomatoes score, was the company's highest viewed original film ever on the service in its first week, and one of the platform's biggest original productions (including sequels, series and additional seasons). The company also said "Bright" is the top movie on Netflix in every country the service is in, with more people overseas watching it than are watching it domestically. The film, costing a reported $90 million to produce, garnered 11 million viewers in its first three days, according to Nielsen measurements, which MarketWatch calculated would be equal to about a $95 million Friday-to-Sunday opening weekend at the box office. Netflix didn't provide a release date for the "Bright" sequel. Shares of Netflix have gained 59% in the trailing 12-month period, while the S&P 500 index is up 20% and the Dow Jones Industrial Average is up nearly 25%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 09:07:03

    UPDATE: Biogen shares drop 3% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 3% in morning trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is also still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Despite the company's Thursday share decline, EvercoreISI analyst Umer Raffat said that the trial wasn't well understood and it shouldn't affect company shares much. "Today, all we learned is that the efficacy delta is ~10%)," Raffat said. "Trial continues to mo 18. This is key." Biogen shares have risen nearly 3% over the last three months, compared with a 7.5% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 06:24:15

    Biogen shares drop 4% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 4.1% in premarket trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Biogen shares have risen 6% over the last three months, compared with a 7% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/19/2017 09:15:40

    Spark to announce gene therapy price in January

    Spark Therapeutics(ONCE) will announce the price for its gene therapy for inherited blindness, Luxturna, which was approved on Tuesday by U.S. regulators, in early January, a Spark spokeswoman said by email. Luxturna is expected to be available late in the first quarter of 2018, she said.

  • 12/14/2017 06:21:07

    Criteo stock plunges on lowered outlook following Apple's iOS update

    Shares of ad-retargeting firm Criteo S.A. fell 12% in premarket trading Thursday after the company dramatically lowered its 2018 revenue forecast due to changes Apple Inc. made to its mobile operating system. Apple's new iOS 11.2 software "disables the solution that some companies in the advertising ecosystem, including Criteo, currently use to reach Safari users," according to a release from Criteo. The company projects this change to reduce 2018 revenue by 22%, excluding traffic acquisition costs, if the firm can't effectively work within the new iOS landscape. Management had previously projected a 9% to 13% "net negative impact." Criteo said that it had a new solution "under development" but also that "its effectiveness cannot be assessed at this early stage." Criteo shares are down 23% this year, while Apple's stock is up 49%. The S&P 500 Index has gained 19%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/13/2017 12:15:16

    Congress secures tax deal, Trump backs 21-percent corporate rate

    WASHINGTON (Reuters) - Congressional Republicans have reached a deal on final tax legislation, the U.S. Senate's top Republican tax writer said on Wednesday, with President Donald Trump saying he would back a sharply lowered corporate tax rate of 21 percent.

  • 12/13/2017 11:30:43

    Senate secures tax deal, Trump backs 21-percent corporate rate

    WASHINGTON (Reuters) - Congressional Republicans have reached a deal on final tax legislation, the top Senate Republican tax writer said on Wednesday, with President Donald Trump saying minutes later he would back a corporate tax rate of 21 percent.

  • 12/13/2017 10:51:50

    Republicans reach deal on final tax legislation

    WASHINGTON (Reuters) - Congressional Republicans have reached a deal on final tax legislation, the top Senate Republican tax writer said on Wednesday, an achievement that would clear the way for final votes in the Senate and House of Representatives next week.

  • 11/29/2017 08:21:45

    Rite Aid's stock rockets on heavy volume for a 2nd-straight day

    Shares of Rite Aid Corp. rocketed on heavy volume Wednesday for a second-straight session, after the drugstore chain said it had completed the "pilot closing" of its amended asset purchase deal with Walgreens Boots Alliance Inc. . The stock shot up 14% to a 2-month high. Volume hit 39 million shares, enough to make it the most active stock on major U.S. exchanges, and already about double the full-day average. On Tuesday, after the stock shot up 16% on volume of 51.5 million shares. Rite Aid said late Monday that the pilot closing resulted in the transfer of 97 stores and related assets to Walgreens. Under the amended agreement announced in September, Rite Aid will sell a total of 1,932 stores, three distribution centers and related inventory for $4.38 billion in cash. Rite Aid expects to use the bulk of the proceeds from the deal to repay debt. Despite the stock's surge this week, it was still down 73.9% year to date, while Walgreen shares have lost 11.5% and the S&P 500 has gained 17.4%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/27/2017 14:28:13

    BRIEF-‍Rite Aid Announces First Closings Of Asset Sale To Walgreens Boots Alliance​

    * ‍RITE AID ANNOUNCES FIRST CLOSINGS OF ASSET SALE TO WALGREENS BOOTS ALLIANCE​ Source text for Eikon: Further company coverage:

  • 11/09/2017 15:32:18

    Disney announces new 'Star Wars' trilogy, live-action TV show

    Walt Disney Co. is making a new "Star Wars" trilogy, the company said in a news release Thursday. Disney said it is tapping Rian Johnson, who directed the upcoming film "Star Wars: The Last Jedi" to write and direct the first of the new films, and create the entire trilogy. The new trilogy will be separate from the Skywalker-themed episodic saga, the company said, and will introduce new characters "from a corner of the galaxy that 'Star Wars' lore has never before explored." In a conference call related to the earnings report Disney released Thursday afternoon, Chief Executive Robert Iger also said that Disney is developing a live-action "Star Wars" television series that will appear on the streaming service the company is planning to launch. Disney stock was up slightly to $103.07 in late trading, after originally falling after the earnings report was released. The stock has dropped 1% this year, as the S&P 500 index has gained 16%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/26/2017 14:05:07

    Dow, S&P 500 close higher; biotech weakness pressures Nasdaq

    The Dow and S&P 500 ended higher on Thursday, supported by a steady stream of healthy earnings, though weakness in the biotechnology sector pressured the Nasdaq. The Dow Jones Industrial Average rose 71 points, or 0.3%, to 23,401. The S&P 500 added 3.3 points to 2,560, a gain of 0.1%. The Nasdaq Composite Index ended down 7 points, or 0.1%, at 6,557. The Nasdaq's weakness came as biotech shares sold off sharply. The iShares Nasdaq Biotechnology ETF lost 2.3% after Celgene Corp. reported disappointing results and cut its outlook. Celgene shares ended 16% lower. On the upside, Twitter Inc. rose 20% on the back of its results while Ford Motor Co. ended up 1%. The stocks of companies in the pharmaceutical supply chain dropped after a report that Amazon has obtained approval to become a wholesale distributor in a number of states. Rite Aid Corp. sank 6.2% while CVS Health Corp. was down 2.9%. CVS shares were also impacted by reports it would buy Aetna . Shares of Aetna ended 11.5% higher. Adding to the buying momentum, the House of Representatives passed a budget blueprint on Thursday, paving the way for the Senate to later pass a tax-reform package.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/26/2017 13:04:42

    Drug stocks drop after report that Amazon has obtained pharmacy licenses

    The stocks of companies in the pharmaceutical supply chain dropped in Thursday afternoon trade after a report by the St. Louis Post-Dispatch that online retailer Amazon has obtained approval to become a wholesale distributor in a number of states. Amazon has received approval in at least 12 states, the St. Louis Post-Dispatch reported. Speculation about an Amazon pharmacy entry has swirled since a CNBC report on the subject earlier this year, but Amazon has repeatedly declined to comment on or confirm any interest in pharmacy. Such a move would likely threaten a number of industry players, including drug wholesalers, pharmacy chains and pharmacy-benefit managers, middlemen that negotiate drug prices. Rite Aid Corp. shares dropped 5.6% in Thursday afternoon trade, CVS Health Corp. shares dropped 4.8%, Express Scripts Holding Company shares dropped 3.5%, McKesson Corp. shares dropped 3.4%, AmerisourceBergen Corp. shares dropped 4.4%, Walgreens Boots Alliance shares dropped 3.7% and Cardinal Health Inc. shares dropped 2.5%, compared with a 0.2% rise in the S&P 500 . Many of the stocks have plunged in the last several months on concerns about Amazon. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/25/2017 10:04:58

    Walgreens to shutter 600 stores as part of Rite Aid deal

    Walgreens plans to close about 600 drugstores as it completes a $4.38 billion deal to buy nearly 2,000 locations from rival Rite Aid

  • More trends:

    RLI Corp.RLI | RLJ Lodging TrustRLJ | Roadrunner Transportation SystemsRRTS | Robert Half International Inc.RHI | Rockwell AutomationROK | Rockwell CollinsCOL | Rogers CommunicationRCI | Rogers CorporationROG | RollinsROL | Roper TechnologiesROP |